Disputable issues of anticoagulant therapy: exacerbation of coronary heart disease and transcutaneous interventions in patients with cardiac fibrillation treated with vitamin K antagonists


Cite item

Full Text

Abstract

The article concerns the policy of anti-platelet treatment in patients with coronary heart disease exposed to transcutaneous coronary interventions. Patients with cardiac fibrillations are specially considered. International trials are reviewed.

About the authors

I S Yavelov

Email: yavelov@yahoo.com

I S Yavelov

References

  1. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J. Am. Coll. Cardiol. 2006; 48: 854-906.
  2. Singer D. E., Albers G. W., Dalen J. E. et al. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 546S-592S.
  3. Harrington R. A., Becker R. C., Cannon C. P. et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 670S-707S.
  4. Goodman S. G., Menon V., Cannon С. Р. et al. Acute ST-segment elevation myocardial infarction. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 708S-775S.
  5. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur. Heart J. 2007; 28: 1598-1660.
  6. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. A Report of the American College of Cardiology/American Heart Association task force on practice guidelines. (Writing committee to revise the 2002 guldelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction). J. Am. Coll. Cardiol. 2007; 50 (7): e1-157.
  7. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association. Task force on practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Доступно в Интернет на сайте www.acc.org.
  8. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur. Heart J. 2008; 29: 2909-2345.
  9. focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 2008; 51: 210-247.
  10. focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 2008; 51: 172-209.
  11. The task Force for percutaneous coronary intervention of the European Society of Cardiology. Guideline for percutaneous coronary intervention. Eur. Heart J. 2005; 26: 804-847.
  12. Douketis J. D., Berger P. B., Dunn A. S. et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 299S-339S.
  13. Brass L. M., Lichtman J. H., Wang Y. et al. Intracranial hemorrhage associated with thrombolytic thеrару for elderly patients with acute myocardial infarction. Results from the cooperative cardiovascular project. Stroke 2000; 31: 1802-1811.
  14. Andreotti F., Testa L., Biondi-Zoccai G. G. L., Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25307 patients. Eur. Heart J. 2006; 27: 519-526.
  15. van Es R. F., Jonker J. J. C., Verheugt F. W. A. et al., for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109-113.
  16. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 2002; 347: 969-974.
  17. OASIS Investigators. Effect of long-term, moderate intensity oral anticoagulation in addition to aspirin in unstable angina. J. Am. Coll. Cardiol. 2001; 37: 475-484.
  18. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001; 345: 494-502.
  19. Becker R. C., Meade T. W., Berger P. B. et al. The primary and secondary prevention of coronary artery disease. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 776S-814S.
  20. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med. 1990; 323: 147-152.
  21. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
  22. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 160S-198S.
  23. Gage B. F., Waterman A. D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke. Results from the National registry of atrial fibrillation. J. A. M. A. 2001; 285: 2864-2870.
  24. Agostoni P., Biondi-Zoccai G. G. L., De Benedictis L. et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures. Systematic overview and meta-analysis of randomized trials. J. Am. Coll. Cardiol. 2004; 44: 349-356.
  25. Karjalainen P. P., Vikman S., Niemela M. et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur. Heart J. 2008; 29: 1001-1010.
  26. Karjalainen P. P., Porela P., Ylitalo A. et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur. Heart J. 2007; 28: 726-732.
  27. Orford J. L., Fasseas P., Melby S. et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am. Heart J. 2004; 147: 463-467.
  28. Mattichak S. J., Reed P. S., Gallagher M. J. et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J. Intervent. Cardiol. 2005; 18: 163-166.
  29. Porter A., Konstantino Y., Iakobishvili Z. et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter. Cardiovasc. Intervent. 2006; 68: 56-61.
  30. Lip G. Y. H., Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130: 1823-1827.
  31. Karjalainen P. P., Porela P., Ylitalo A., et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur. Heart J. 2007; 28: 726-732.
  32. DeEugenio D., Kolman L., DeCaro M. et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007; 27: 691-696.
  33. Rubboli A., Colletta M., Herzfeld J. et al. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron. Artery Dis. 2007; 18: 193-199.
  34. Ruiz-Nodar J. M., Marin F., Hurtado J. A. et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation. J. Am. Coll. Cardiol. 2008; 51: 818-825.
  35. Rogacka R., Chieffo A., Michev I. et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J. Am. Coll. Cardiol. Intv. 2008; 1: 56-61.
  36. Nguyen M. C., Lim Y. L., Walton A. et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global registry of acute coronary events: is it safe and effective to use just one antiplatelet agent? Eur. Heart J. 2007; 28: 1717-1722.
  37. Wang T. Y., Robinson L. A., Ou F.-S. et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am. Heart J. 2008; 155: 361- 368.
  38. Rubboli A., Halperin J. L., Airaksinen K. E. J. et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann. of Med. 2008; 40: 428-436.
  39. Chuen K., Lam H. K., Chu R. M. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002; 346: 2033- 2038.
  40. Chan F. K., Ching J. Y., Hung L. C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 2005; 352: 238-244.
  41. Lai K. C., Chu K. M., Hui W. M. et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin. Gastroenterol. Hepatol. 2006; 4: 860-865.
  42. ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology foundation task force on clinical expert consensus documents. Circulation 2008; 118: 1894-1909.
  43. Gilard M., Arnaud В., Cornily J. C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidigrel Aspirin) study. J. Am. Coll. Cardiol. 2007; 51: 256-260.
  44. Gurbel P. A., Lau W. C., Tantry U. S. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol. 2007; 51: 261-263.
  45. Sibbing D., Morath Т., Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 2009; 101: 714-719.
  46. Sibbing D., Braun S., Morath Т. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 2009; 53: 849-856.
  47. Serebruany V., Goto S. Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit? Thromb. Haemost. 2009; 101: 607-609.
  48. Ho P. M., Maddox T. M., Wang L. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J. A. M. A. 2009; 301: 937-944.
  49. Juurlink D. N., Gomes Т., Ko D. T. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; doi: 10.1503/cmaj.082001. Доступно на: http://www.cmaj.ca.
  50. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). 2009. January 26. Доступно на: http://www.fda.gov/ cder/drug/early_comm/clopidogrel_bisulfate.htm.
  51. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
  52. Hylek E. M., Go A. S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 2003; 349: 1019-1026.
  53. Prevention of prematurel discontmuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the american Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-818.
  54. Stone G. W., Moses J. W., Ellis S. G. et al. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. N. Engl. Med. 2007; 356: 998-1008.
  55. Doyle В., Rihal C. S., O'Sulliva C. J. et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007; 116: 2391-2398.
  56. Stone G. W., Ellis S. G., Colombo A. et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007; 115: 2842-2847.
  57. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
  58. Kuchulakanti P. K., Chu W. W., Torguson R. et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.
  59. Iakovou I., Schmidt Т., Bonizzoni E. et al. Incidence, predictors, and outcomeof thrombosis after successful implantation of drug-eluting stents. J. A. M. A. 2005; 293: 2126-2130.
  60. Daemen J., Wenaweser P., Tsuchida K. et al. Early and late coronary stent thrombosis of sirolimueluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
  61. van Werkum J. W., Heestermans A. A., Zomer A. C. et al. Predictors of coronary stent thrombosis: The Dutch stent thrombosis registry. J. Am. Coll. Cardiol. 2009; 53: 1399-1409.
  62. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
  63. Hirsh J., Bhatt D. L. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch. Intern. Med. 2004; 164: 2106-2110.
  64. Lanas A., Garcia-Rodriguez L. A., Arroyo M. T. et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
  65. Guyatt G. H., Cook D. J., Jaeschke R. et al. Grades of recommendation for antithrombotic agents. American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 123S-131S.
  66. Beyth R. J., Quinn L. M., Landefeld S. et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am. J. Med. 1998; 105: 91- 99.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies